Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 113

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 113
---
555 1,540,956 Total liabilities and stockholders’ equity$1,471,237 $1,663,199 

See accompanying Notes to Condensed Consolidated Financial Statements.

1

Table of Contents    

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended June 30,Six Months Ended June 30,(In thousands, except share and per share data)2025202420252024Revenues:Product revenue, net$12,455 $8,615 $21,181 $16,804 Total revenue12,455 8,615 21,181 16,804 Operating expenses:Cost of sales$1,702 $1,495 $2,787 $2,122 Research and development91,940 77,401 164,683 146,021 Selling, general and administrative45,869 35,536 87,396 66,550 Total operating expenses139,511 114,432 254,866 214,693 Loss from operations(127,056)(105,817)(233,685)(197,889)Interest income, net14,513 8,120 30,600 17,009 Other income, net523 1,579 1,776 3,213 Net loss$(112,020)$(96,118)$(201,309)$(177,667)Net loss per share - basic and diluted$(1.93)$(1.69)$(3.49)$(3.14)Weighted-average number of common shares used in computing net loss per share – basic and diluted57,932,576 56,802,546 57,697,193 56,593,011 

See accompanying Notes to Condensed Consolidated Financial Statements.

2

Table of Contents    

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

Three Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Net loss$(112,020)$(96,118)$(201,309)$(177,667)Other comprehensive income (loss)Unrealized gain (loss) on available-for-sale securities290 42 2,173 (604)Comprehensive loss$(111,730)$(96,076)